The benefit of quadruplet regimens in newly diagnosed multiple myeloma (NDMM), as demonstrated by multiple clinical trials, builds on the established efficacy of triplet regimens for patients with NDMM. Recent advances have led several MM thought leaders to consider discarding the potentially outdated terminology of ‘transplant eligible’ and ‘transplant ineligible’ as now we have effective therapies for all patients in the newly diagnosed setting. Quadruplet induction therapy, coupled with risk-adapted maintenance strategies, represents a significant step forward in personalized cancer treatment.

The aim of this CME initiative is to inform learners about these new and evolving treatment options and their role in the clinical setting including:

• The latest efficacy data for quadruplet therapy in NDMM

• Awareness and management of treatment-related adverse events with treatment strategies

• The role of MRD negativity on patient outcomes in NDMM

Please be sure to join for any or all the events listed below. Activity links will be “live” on each activity page on the program launch date. Video and tweetorial activities can be viewed live and will also be archived for later viewing on the individual activity pages linked below.